Key facts
- This page summarizes Chris Nolet's Form 4 filing for ArriVent BioPharma, Inc. (AVBP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 22 Jun 2026, 21:46.
Chris Nolet - 18 Jun 2026 Form 4 Insider Report for ArriVent BioPharma, Inc. (AVBP)
- Reporting relationship
- Director
- Issuer ticker
- AVBP
- Reported as of
- 18 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Jun 2026, 21:46:12 UTC
- Prior SEC filing
- 03 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ James Kastenmayer, Attorney-in-Fact for: Chris Nolet
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Chris Nolet filed Form 4 for ArriVent BioPharma, Inc. (AVBP) on 22 Jun 2026.
Change
- Previous filing in this sequence was filed on 03 Jul 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001782814
Primary reporting owner
Nolet Chris
- Relationship
- Director
- Address
- C/O ARRIVENT BIOPHARMA, INC., 18 CAMPUS BOULEVARD SUITE 100, NEWTOWN SQUARE
- Signature
- By: /s/ James Kastenmayer, Attorney-in-Fact for: Chris Nolet
- Signature date
- 22 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVBP
transaction
Derivative
Non-Qualified Stock Option (right to buy)
Award
- Transaction value
- Shares
- +13,562
- Change %
- Price
- $0.000000*
- Shares after
- 13,562
- Date
- 18 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,562
- Exercise price
- $31.74
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.